Posted by Michael Wonder on 23 Apr 2022
Medexus Pharmaceuticals announces resubmission of treosulfan NDA
22 April 2022 - Additional data collection and analysis reconfirms confidence in new drug application for treosulfan.
Medexus Pharmaceuticals and medac are pleased to announce that medac has resubmitted its new drug application for treosulfan with the U.S. FDA.
